ANTIPROLIFERATIVE, ADME AND POTENTIAL IN SILICO G6PDH INHIBITORY ACTIVITY OF NOVEL 2-(1-BENZOFURAN-2-YL)-4-(5-PHENYL-4H-1, 2, 4-TRIAZOL-3-YL) QUINOLINE DERIVATIVES
DOI:
https://doi.org/10.22159/ijpps.2016v8i11.14791Keywords:
Benzofuran, quinoline, triazole, antiproliferative, Glucose-6-phosphate dehydrogenaseAbstract
Objectives: Synthesis of new 2-(1-benzofuran-2-yl)-4-(5-phenyl-4H-1, 2, 4-triazol-3-yl) quinoline and its derivatives for antiproliferative potential against cancer cells.
Methods: The general methods were employed for the synthesis and the structures were confirmed by IR, 1H-NMR, 13C-NMR and mass spectral analysis. The antiproliferative activity was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and molecular docking study were performed by Auto Dock Tools. In silico Absorption-Distribution-Metabolism-Excretion-Toxicity (ADMET) study for the drug, likeliness was carried out on ACD/lab-2.
Results: The compound 3l showed 44, 44, 38 and 37 % inhibition against MCF-7, HepG2, Colo205 and HeLa cell lines, respectively; whereas, the compounds 3i and 3j exhibited 49 and 42 % inhibition against MCF-7 cell line. The molecular docking study revealed that the compound 3i has the lowest binding energy (-8.60 Kcal mol-1), suggesting to be potentially best inhibitor of Glucose-6-phosphate dehydrogenase (G6PDH). The in silico ADME analysis also revealed that compound 3i does not violate any of the Lipinski rules of five and has the best stimulative human colonic absorption up to 95 %.
Conclusion: The study reveals that the compounds containing benzofuran coupled nitrogen heterocycles are essential for activity as they possess excellent drug-like characteristics.Â
Downloads
References
Jemal A, Center MM, De Santis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:359-86.
Papac RJ. Origins of cancer therapy. Yale J Biol Med 2001;74:391-8.
Frei EIII, Elias A, Wheeler, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res 1998;4:2027-37.
Padmavathi V, Reddy GS, Padmaja A, Kondaiah P, Ali-Shazia. Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2, 4-triazoles. Eur J Med Chem 2009;44:2106-12.
Mathew V, Keshavayya J, Vaidya VP, Giles D. Studies on the synthesis and pharmacological activities of 3, 6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues. Eur J Med Chem 2007;42:823-40.
Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?. Cancer Treat Rev 2004;30:325-32.
Demirbas N, Karaoglu SA, Demirbas A, Sancak K. Synthesis and antimicrobial activities of some new 1-(5-phenylamino-[1,3,4]thiadiazol-2-yl)methyl-5-oxo-[1,2,4] triazole and 1-(4-phenyl-5-thioxo-[1,2,4] triazol-3-yl)methyl-5-oxo-[1,2,4] triazole derivatives. Eur J Med Chem 2004;39:793-804.
Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Highly potent triazole based tubulin polymerization inhibitors. J Med Chem 2007;50:749-54.
Satyanarayan ND, Santoshkumar S, Sheelavanth S, Yadav DB, Anantacharya R, Sandeep T. Antitubercular, antibacterial and molecular docking studies of new 2 (naphtha [2, 1-] furan-2-yl) quinoline-4-carboxylic acids and their esters. Inventi Impact: Med Chem 2016;2016:75-83.
Anantacharya R, Manjulatha K, Satyanarayan ND, Santoshkumar S, Kaviraj MY. Antiproliferative, DNA cleavage, and ADMET study of substituted 2-(1-benzofuran 2 yl) quinoline-4-carboxylic acid and its esters. Cogent Chem 2016;2:1158382.
Manjunatha K, Siddappa, Manjulatha K, Satyanarayan ND, Kaviraj MY, Adarsha HJ. Anti-proliferative and ADMET screening of novel 3-(1H-indol-3-yl) 1, 3-diphenylpropan1-one derivatives. Cogent Chem 2016;2. http://doi.org/10.1080/ 23312009.2016.1172542
Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radical Biol Med 2012;53:421-36.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46:3-26.
Sheelavanth Shanker Rao. Ph. D. Thesis, Kuvempu University; 2013.
Leite TB, Gomes D, Miteva MA, Chomilier J, Villoutreix BO, Tufféry P. Frog: a free online drug 3D conformation generator. Nucleic Acids Res 2007;35:568-72.
Wojciechowski M, Milewski S, Mazerski J, Borowski E. Glucosamine-6-phosphate synthase, a novel target for antifungal agents. Molecular modelling studies in drug design. Acta Biochim Pol 2005;52:647-53.
Banerjee K, Gupta U, Gupta S, Wadhwa G, Gabrani R, Sharma SK, et al. Molecular docking of glucosamine-6-phosphate synthase in rhizopus oryzae. Bioinformation 2011;7:285-90.
Chen S, Kao YC, Laughton CA. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. J Steroid Biochem Mol Biol 1997;61:107-15.
Published
How to Cite
Issue
Section
